Kazia Therapeutics Limited (ASX:KZA)
Kazia Therapeutics Limited (ASX:KZA) is an oncology-focused drug development company. Kazia's lead program is paxalisib, a brain-penetrant inhibitor which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults.
Licensed from Genentech in late 2016, paxalisib was granted Orphan Drug Designation for glioblastoma by the US FDA in 2018, and Fast Track Designation for glioblastoma by the US FDA in 2020. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Designation by the US FDA for DIPG in August 2020.
Paxalisib commenced recruitment to GBM AGILE, a pivotal study in glioblastoma, in January 2021. Seven additional studies are active in other forms of brain cancer.